Information  X 
Enter a valid email address

Amryt Pharma PLC (AMYT)

  Print      Mail a friend

Wednesday 03 June, 2020

Amryt Pharma PLC

Director/PDMR Shareholding

RNS Number : 8329O
Amryt Pharma PLC
03 June 2020
 

3 June 2020

 

Amryt Pharma plc

("Amryt" or the "Company")

 

Director/PDMR shareholding

This announcement, including the details included in the notification below, is made in accordance with the requirements of the EU Market Abuse Regulation.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1. 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Ray Stafford

2.

Reason for the notification

a)

Position / status

Non-executive Chairman

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Amryt Pharma plc

b)

Legal entity identifier

213800YNUJEOJ84L4T95

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of 0.06 each

 

 

Identification code

ISIN: GB00BKLTQ412

b)

Nature of the transaction

Purchase of ordinary shares 

d)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

110p

50,000

 

e)

Aggregated information

-  Aggregated volume

 

-  Aggregated price

 

Aggregated total

 

50,000

 

110p

 

£55,000

 

f)

Date of the transaction

20 May 2020

g)

Place of the transaction

London Stock Exchange (AIM)

 

 

Enquiries

  Amryt Pharma plc

+353 (1) 518 0200

  Joe Wiley, CEO

  Rory Nealon, CFO/COO

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHKKNBBKBKDFAK

a d v e r t i s e m e n t